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ABSTRACT 
The process of mucoadhesion involving a polymeric drug delivery system is a complex one that includes 
processes such as wetting, adsorption and interpenetration of polymer chains. The success and degree of 
mucoadhesion bonding is influenced by various polymer-based properties such as the degree of cross-
linking, chain length and the presence of various functional groupings. The attractiveness of mucosal-
targeted controlled drug delivery of active pharmaceutical ingredients, has led formulation scientists to 
evaluate numerous polymeric systems for such tasks. Formulation scientists have at their disposal a range of 
in vitro and in vivo mucoadhesion testing setups in order to select candidate adhesive drug delivery system. 
As such, mucoadhesive systems have found wide use throughout many mucosal covered organelles for active 
ingredients delivery for local or systemic effect. Evolution of such mucoadhesive formulations has 
transgressed from first-generation charged hydrophilic polymer networks to more specific second-generation 
systems based on lectin, thiol and various other adhesive functional groups. 
 
KEYWORDS: Mucoadhesive drugs, mucoadhesive polymers, mucoadhesive routes, Evaluation  
 
 
 
 
 
 
 
* For Correspondence  
Mrs. Jyotsana Madan.  
Asst. Prof: – Dept. of Pharmaceutics. 
S. No. 44/1, Vadgaon (Bk), Off. Sinhgad Road, 
Pune –  411041, MAHARASHTRA. 
Email: jrmadan@hotmail.com 
Phone. No.: 9420148817 
Telefax: - 020-2435472 
 
 Madan J et al / IJRAP 2010, 1 (1) 63-70 
International Journal of Research in Ayurveda & Pharmacy, Volume 1, Issue 1, Sep-Oct 2010  63-70 
INTRODUCTION 
The concept of mucoadhesion was introduced in the field of controlled release drug delivery systems in the 
early 1980s
1,2
•          Buccal /oral route 
.  Thereafter, several researchers have focused on the investigations of the interfacial 
phenomena of mucoadhesive hydro gels with the mucus. For drug delivery purpose, the term bioadhesion 
implies attachment of a drug carrier system to a specific biological location. The biological surface can be 
epithelial tissue. If adhesive attachment is to a mucus coat, the phenomenon is referred to as mucoadhesion. 
Hence a bacterial attachment is to tissue surfaces, and mucoadhesion can be modeled after the adherence of 
mucus on epithelial tissue. Mucoadhesion is the relatively new and emerging concept in drug delivery. 
Mucoadhesion keeps the delivery system adhering to the mucus membrane. By this definition, the mucosal 
routes for drug delivery are: 
•  Nasal route 
•  Ocular route 
•  Vaginal route 
•  Gastrointestinal route 
 
NEED OF MUCOADHESIVE DELIVERY 
As compared to oral controlled release systems, mucoadhesive delivery system have several advantages by 
virtue of prolongation of residence time, drug targeting, intimate contact between dosage form and the 
absorptive mucosa. In addition, mucoadhesive dosage forms have been used to target local disorders at the 
mucosal surface to reduce dose and to minimize the side effects. Mucoadhesive formulations use polymers as 
the adhesive component. These polymers are often water soluble and when used in a dry form, they attract 
water from the mucosal surface and this water transfer leads to a strong interaction further increasing the 
retention time over the mucosal surfaces and leads to adhesive interactions.
 Prolonged contact time of a drug 
with a body tissue through the use of a bioadhesive polymer can significantly improve the performance of 
many drugs
2. 
 
MECHANISM OF MUCOADHESION 
The mechanism of  mucoadhesion between hydrogels and mucosa can be described in three steps. 
1. Wetting and swelling  
2. Interpenetration of the bioadhesive polymer  
3. Formation of weak chemical bonds
3.
 
 
MUCOADHESIVE POLYMERS 
Properties 
1. It must be loaded substantially by the active compound. 
2. Swell in the aqueous biological environment of the delivery–absorption site. 
3. Interact with mucus or its components for adequate adhesion. 
4. When swelled they allow, controlled release of the active compound. 
5. Be excreted unaltered or biologically degraded to inactive, non-toxic oligomers. 
6. Sufficient quantities of hydrogen bonding chemical groups. 
7. Possess   high molecular weight. 
8. Possess   high chain flexibility. 
9. Surface tension that will induce spreading into mucous layer
2 
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Classification
 
Mucoadhesive polymer are classified as follows: 
First generation polymer: 
Anionic polymer: poly(-acrylic acid), carbopol, polycarbophil, 
Cationic polymer: Chitosan 
Second generation polymer: Lecitins, bacterial adhesion 
New generation polymer: Thiomers 
 
POLYMER PROPERTIES DESIRABLE FOR  MUCOADHESION 
Functional group  
The mucoadhesive polymer possessing hydrophilic functional group such as COOH, OH, NH2, and SO4H 
may be more favourable in formulating targeted drug delivery system. The functionalized polymer interact 
with mucus not only through physical entanglement but also through chemical bonds, resulting in formation 
of cross linked network. Example: Urea is well accepted hydrogen bonding disruptor which decreases 
mucoadhesiveness of mucin/pectin samples
5,6. 
 
Degree of hydration 
 
Hydration is essential for the relaxation and interpenetration of polymer chains. Excess of hydration could 
lead to decreased mucoadhesion and/or retention due to the formation of a slippery mucilage. In this situation 
cross-linked polymers that only permit a certain degree of hydration may be advantageous for providing a 
prolonged mucoadhesive effect
7,8,9. 
 
Chain length
 
Chain length and its flexibility is critical for interpenetration and entanglement with the mucus gel. Increased 
chain mobility leads to increased inter diffusion and interpenetration of the polymer within the mucus 
network. Long polymer chains lose their ability to diffuse and interpenetrate through mucosal surfaces. 
Hence as the chain length decreases interpenetration increases
10,11.
  
 
Degree of cross linking  
The chain mobility and resistance to dissolution is significantly influenced by the degree of cross-linking 
within a polymer system. Cross-linked hydrophilic polymers swell in the presence of water allowing them to 
retain their structure. High molecular weight linear hydrophilic polymers are swellable and readily 
dispersible. Cross-link density increases, chain mobility decreases and hence the effective chain length, 
decreases, reducing  mucoadhesive strength
12. 
 
Polymer concentration 
Polymer concentration is dependent on physical state of the delivery system, with differences between 
semisolid and solid-state dosage form. In the semisolid state, polymer concentration is low which reduces 
adhesion. Hence lower number of polymer chains are available for interpenetration with mucus. On the other 
hand, solid dosage forms such as buccal tablets exhibit increased adhesive strength as the mucoadhesive 
polymer concentration increases
13. 
 
COMMON SITES OF APPLICATION FOR MUCOADHESIVE DRUG DELIVERY PLATFORM 
Mucoadhesive formulations have been widely used for their targeted and controlled release delivery to many 
mucosal membrane-based organelles. Such formulations may deliver active ingredient for local or systemic 
effect, while bioavailability limiting effects such as enzymatic or hepatic degradation can be avoided or 
minimised. 
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Buccal drug delivery 
The buccal cavity offers many advantages for drug delivery application. The most significant advantage 
offered is high accessibility and low enzymatic activity. Additionally, buccal drug delivery can be promptly 
terminated in cases of toxicity through the removal of dosage form thereby offering a safe and easy method 
of drug utilisation
19. Various polymers such as sodium carboxymethylcellulose, hydroxypropylcellulose and 
polycarbophil are used for delivery of  peptides, protein and polysaccharides by this routes  have been 
examined
20,21,22. Although gel and ointments are the most patient convenient; tablets, patches and films have 
also been examined. Furthermore buccal drug delivery is associated with high patient compliance, low levels 
of irritation and offers significant ease of administration
23,24. 
 
Opthalmic drug delivery 
The delivery of therapeutic agents to the eye may be achieved using various types of dosage forms including 
liquid drops, gels, ointments and solid ocular inserts (both degradable and nondegradable)
25,26,.Another 
interesting delivery system is in situ gelling polymer that undergoes a phase transition after application. 
Mucoadhesive polymers would be expected only to attach to conjunctival mucus in vivo. Additionally 
limited bioavailability has been experienced in vivo for carbomer and polycarbophil,
27 as a result of the high 
swelling capacity of such polymers in the neutral pH environment of the eye. Maintenance of a low viscosity 
in such systems through pH regulation in the range 4–5 is not acceptable as it may result in patient unease 
and mild lacrimation, both of which will have an effect on treatment success. User acceptance and 
compliance may subsequently be limited by physical and psychological barriers surrounding such dosage 
forms
28. 
 
Vaginal drug delivery systems 
Vaginal drug delivery offers many advantages; the avoidance of hepatic first-pass metabolism, a decrease in 
hepatic side effects and avoidance of pain, tissue damage, and infection commonly observed for parenteral 
drug delivery routes of administration. While the vagina provides a promising site for systemic drug delivery 
because of its large surface area, rich blood supply and high permeability, poor retention due to the self-
cleansing action of the vaginal tract is often problematic. However, residence times within the vagina tend to 
be much higher than at other absorption sites such as the rectum or intestinal mucosa. Another important 
consideration is the change in the vaginal membrane during the menstrual cycle and post-menopausal period. 
Typical bioadhesive polymers that have been in vaginal formulations include polycarbophil, 
hydroxypropylcellulose and polyacrylic acid
29-35. 
 
Nasal drug delivery 
One of the key advantages provided by intranasal drug delivery is that the nasal cavity provides a large 
highly vascularised surface area through which first-pass metabolism can be avoided, as blood is drained 
directly from the nose into the systemic circulation. Successful nasal delivery has been obtained using 
solutions, powders, gels and microparticles. The most commonly employed intranasal active ingredient are 
solutions containing sympathomimetic vasoconstrictors for immediate relief of nasal congestion. Local 
delivery of these alpha adrenergic stimulators is of particular benefit to patients with high blood pressure (or 
those at heightened risk of cardiovascular incident), as vasoconstriction will occur to the greatest degree 
within the nose. In addition to local effects, the intranasal route of drug administration has also been used to 
achieve a distal systemic effect. One such example is the intranasal delivery of the peptide desmopressin that 
exerts its action on the kidneys, mimicking the action of antidiuretic hormone, used mainly in Diabetes 
insipidus
36,37. 
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EVALUATION OF MUCOADHESIVE DRUG DELIVERY SYSTEMS
 
Measuring the force of attachment 
The adhesive strength at bonding interface can be measured by measuring the force required to detach one 
entity from the other through the application of an external force. Hence the destruction of adhesive bond is 
usually under the application of either a shearing, tensile or peeling force
38,39 
In vitro residence time study 
The mucoadhesive properties of tablets were evaluated by in vivo residence time study as reported by Lehr et 
al
40. A 1-cm by 1-cm piece of porcine buccal mucosa was tied onto a glass slide (3-inch by 1-inch) using 
thread. Tablet was stuck onto the wet, rinsed, tissue specimen, by applying light force with a fingertip for 30 
seconds. The prepared slide was hung onto one of the groves of a USP tablet disintegrating test apparatus. 
The disintegrating test apparatus was operated such that the tissue specimen was given regular up and down 
movements in a beaker containing the dissolution medium (0.01 N HCl). At the end of 3 hour, the 
detachment of tablet from tissue was checked and the time of detachment was recorded as the in vivo 
residence time. 
 
GI transit study using radio-opaque markers 
It is a simple procedure involving the use of radio-opaque markers, e.g. barium sulfate, encapsulated in 
bioadhesive  to determine the effectss of bioadhesive polymers on GI transit time. Faeces collection (using an 
automated faeces collection machine) and X-ray inspection provide a non-invasive method of monitoring 
total GI residence time without affecting normal GI motility.  
 
Fluorescent probe method 
In this method the membrane lipid bilayered and membrane proteins were labeled with pyrene and fluorescein 
isothiocyanate, respectively. The cells were mixed with the mucoadhesive agents and changes in fluorescence 
spectra were monitored. This gave a direct indication of polymer binding and its influence on polymer adhesion.  
 
Thumb test 
The adhesiveness is measured by the difficulty of pulling the thumb from the adhesive as a function of the 
pressure and the contact time. Although the thumb test may not be conclusive, it provides useful information on 
peel strength of the polymer. 
 
CONCLUSION 
The focus of pharmaceutical research is being steadily shifted from the development of new chemical entities to 
the development of novel drug delivery system (NDDS) of existing drug molecule to maximize their effect in 
terms of therapeutic action and patient protection. Mucoadhesive systems are known to provide intimate contact 
between dosage form and the absorptive mucosa, resulting thereby in a high drug flux through the absorbing 
tissue. 
 In addition, mucoadhesive dosage forms have been used to target local disorders at the mucosal surface to 
reduce the overall dosage required and to minimize the side effects that may be caused by the systemic 
administration of the drugs. 
 
 
 
.  
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Table.1. Theory of Mucoadhesion 
 
SR.N
O 
Theory Mechanism of bioadhesion 
[4]  Comments 
     1.  Electronic theory  Attractive electrostatic forces between 
glycoprotein mucin network and the 
bioadhesive material 
Electron transfer occur between the 
two forming  double layer of electric 
charge at the interface. 
     2.  Adsorption 
theory 
Surface forces resulting in chemical 
bonding 
Strong primary forces: covalent 
bonds, weak secondary force: ionic 
bonds, hydrogen bonds and Vander 
Waal’s forces.   
     3.  Wetting theory  Ability of bioadhesive polymer to 
spread and develop intimate contact 
with the mucus membrane. 
Spreading coefficient of polymer 
must be positive. 
     4.  Diffusion theory   Physical entanglement of mucin 
strands and the flexible polymer chain 
For maximum diffusion and best 
bioadhesive strength and solubility 
parameters(δ)  of  the  bioadhesive 
polymer and the mucus glycoprotein 
must be similar.  
 
Table.2 Various Polymer Used In Drug Delivery System 
 
Polymers
[14-18] Properties      Examples 
Poly(cyano acrylate)  Biodegradable depending on 
the length of the alkyl chain. 
• Used as surgical adhesives 
and glues. 
• Potentially used in drug 
delivery. 
Polyphosphazenes  Can be tailored with versatile 
side chain functionality 
• Can be made into films and 
hydrogels. 
• Applications in drug 
delivery. 
Poly (vinyl alcohol)  Biocompatible  • Gels and  blended  
membranes are used in drug 
delivery and cell 
immobilization. 
Poly (hydroxytheyl 
methacrylate) 
 Biocompatible  • Hydrogels have been used 
as soft contact lenses, for 
drug delivery, as skin 
coatings, and for 
Immunoisolation  
membranes. 
Poly (ethylene oxide-b-
propylene oxide) 
Surfactants with amphiphilic 
properties. 
• Used in protein delivery and 
skin treatments. 
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